Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 nov. 2017 06h00 HE | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate...
07 nov. 2017 06h00 HE | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Third Quarter 2017 Financial Results

BCX7353 Phase 3 program agreed with FDA and EMA U.S. Orphan Drug designation for BCX7353 received from FDA RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals,...
01 nov. 2017 06h00 HE | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at the Jefferies 2017 London Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate...
27 oct. 2017 06h00 HE | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAI’s 2017 Annual Scientific Meeting

RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that results from its successful Phase 2 APeX-1 clinical trial in...
24 oct. 2017 06h00 HE | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Announce Third Quarter 2017 Financial Results on November 7

RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its third quarter 2017 financial results will be reported on...
04 oct. 2017 06h00 HE | Source: BioCryst Pharmaceuticals

BioCryst Announces RAPIVAB® (peramivir injection) and Galidesivir Presentations at IDWeek 2017™

RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that interim results from a clinical trial of a single IV dose of...
21 sept. 2017 06h00 HE | Source: BioCryst Pharmaceuticals

BioCryst’s RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a biotechnology company focused on the development and commercialization of treatments...
15 sept. 2017 12h00 HE | Source: BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced today the completion of an underwritten public offering of 17,864,078 shares...
12 sept. 2017 21h00 HE | Source: BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Prices Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced today the pricing of an underwritten public offering of 15,533,981 shares of...
11 sept. 2017 16h01 HE | Source: BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Commences Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) a biotechnology company focused on the development and commercialization of treatments...

Page précédente